The company said that recent regulatory and reimbursement decisions have been favorable and will help spur adoption of clinical NGS testing.
CytoReason's machine-learning algorithms extract information from multi-omic measurements to improve indication prioritization and highlight new treatment targets.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
The firm aims to offer a clinical service next year for predicting immunotherapy response and adverse immune reactions.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
Plenary session Chairwoman Elaine Mardis said the presentations made it clear how great the need is for interdisciplinary science as data becomes ever more complex.
The companies plan to commercialize MIODx's immune sequencing technology for diagnostic purposes.
The companies plan to develop a broad NGS panel to analyze all known biomarkers for cancer drugs, including tumor mutation burden and microsatellite instability.
Researchers find that a personalized ovarian cancer vaccine appears safe, the Los Angeles Times reports.
The companies are aiming to develop and establish clinical operation for the assays in Japan, where Hitachi said there is growing demand for such tests.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.